X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AANJANEYA LIFECARE with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. DATSONS LABS vs LUPIN LTD - Comparison Results

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. DATSONS LABS LUPIN LTD DR. DATSONS LABS/
LUPIN LTD
 
P/E (TTM) x -10.9 28.4 - View Chart
P/BV x 0.2 3.0 5.5% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 DR. DATSONS LABS   LUPIN LTD
EQUITY SHARE DATA
    DR. DATSONS LABS
Mar-14
LUPIN LTD
Mar-18
DR. DATSONS LABS/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs1261,465 8.6%   
Low Rs31727 4.2%   
Sales per share (Unadj.) Rs133.0349.6 38.0%  
Earnings per share (Unadj.) Rs0.25.6 2.7%  
Cash flow per share (Unadj.) Rs6.629.6 22.3%  
Dividends per share (Unadj.) Rs05.00 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs128.8300.3 42.9%  
Shares outstanding (eoy) m31.66452.08 7.0%   
Bonus/Rights/Conversions FCCBESOPS-  
Price / Sales ratio x0.63.1 18.8%   
Avg P/E ratio x516.1197.2 261.7%  
P/CF ratio (eoy) x11.837.1 32.0%  
Price / Book Value ratio x0.63.6 16.6%  
Dividend payout %090.0 0.0%   
Avg Mkt Cap Rs m2,477495,502 0.5%   
No. of employees `000NA17.0 0.0%   
Total wages/salary Rs m5628,647 0.2%   
Avg. sales/employee Rs ThNM9,273.6-  
Avg. wages/employee Rs ThNM1,681.0-  
Avg. net profit/employee Rs ThNM147.4-  
INCOME DATA
Net Sales Rs m4,211158,042 2.7%  
Other income Rs m791,504 5.2%   
Total revenues Rs m4,289159,545 2.7%   
Gross profit Rs m56931,475 1.8%  
Depreciation Rs m20410,859 1.9%   
Interest Rs m4302,044 21.1%   
Profit before tax Rs m1320,076 0.1%   
Minority Interest Rs m0-71 0.0%   
Prior Period Items Rs m-235 -5.1%   
Extraordinary Inc (Exp) Rs m0-14,644 0.0%   
Tax Rs m62,885 0.2%   
Profit after tax Rs m52,513 0.2%  
Gross profit margin %13.519.9 67.8%  
Effective tax rate %48.014.4 334.3%   
Net profit margin %0.11.6 7.2%  
BALANCE SHEET DATA
Current assets Rs m6,852122,095 5.6%   
Current liabilities Rs m6,71150,956 13.2%   
Net working cap to sales %3.345.0 7.4%  
Current ratio x1.02.4 42.6%  
Inventory Days Days16185 190.1%  
Debtors Days Days318120 265.6%  
Net fixed assets Rs m3,673129,876 2.8%   
Share capital Rs m317904 35.0%   
"Free" reserves Rs m3,761134,866 2.8%   
Net worth Rs m4,078135,771 3.0%   
Long term debt Rs m1,67164,245 2.6%   
Total assets Rs m12,633263,054 4.8%  
Interest coverage x1.010.8 9.5%   
Debt to equity ratio x0.40.5 86.6%  
Sales to assets ratio x0.30.6 55.5%   
Return on assets %3.41.7 198.8%  
Return on equity %0.11.9 6.4%  
Return on capital %7.73.7 206.3%  
Exports to sales %22.90-   
Imports to sales %14.30-   
Exports (fob) Rs m964NA-   
Imports (cif) Rs m602NA-   
Fx inflow Rs m96453,141 1.8%   
Fx outflow Rs m60719,335 3.1%   
Net fx Rs m35733,807 1.1%   
CASH FLOW
From Operations Rs m1,34517,512 7.7%  
From Investments Rs m-2,256-14,073 16.0%  
From Financial Activity Rs m-1,200-14,921 8.0%  
Net Cashflow Rs m-2,111-11,482 18.4%  

Share Holding

Indian Promoters % 4.5 46.6 9.7%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 0.0 11.3 -  
FIIs % 1.4 31.9 4.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 94.1 10.1 931.7%  
Shareholders   20,807 98,259 21.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. DATSONS LABS With:   STERLING BIOTECH  SANOFI INDIA  ALEMBIC PHARMA  ORCHID PHARMA LTD  PFIZER  

Compare DR. DATSONS LABS With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Recovers after Crashing Over 1000 Points; DHFL Tanks 50%(01:30 pm)

Stock markets in India plunged in the afternoon session today. The BSE Sensex recovered after tanking 1,000 points in intra-day deals.

Related Views on News

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

LUPIN LTD Announces Quarterly Results (1QFY19); Net Profit Up 21.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, LUPIN LTD has posted a net profit of Rs 4 bn (up 21.3% YoY). Sales on the other hand came in at Rs 26 bn (up 3.2% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Hindustan Aeronautics IPO: Yet Another Play on India's Defence Sector (IPO)

Mar 14, 2018

Should you apply for the IPO of state-run military aircraft maker Hindustan Aeronautics?

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. DATSONS LABS SHARE PRICE


May 21, 2015 (Close)

TRACK DR. DATSONS LABS

  • Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. DATSONS LABS

DR. DATSONS LABS 8-QTR ANALYSIS

COMPARE DR. DATSONS LABS WITH

MARKET STATS